Latest Seliciclib Stories
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene.
Patients with a specific kind of lung cancer may benefit from a Phase III clinical trial offered by the Moores UCSD Cancer Center.
M. D. Anderson researchers find better way to predict prognosis in patients treated with aromatase inhibitors; research also suggests a potential means of circumventing drug resistance.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today that an independent data review committee (IDRC) has completed a review of the first interim analysis data from the Phase 2b seliciclib APPRAISE study.
Cyclacel Pharmaceuticals, Inc.
- The governor of a province or people.